iLite® Cell-based Solutions
Svar specializes in creating cell-based Reporter Gene Assays with iLite® technology for a range of applications. This technology offers a precise, sensitive system with luciferase readout, suitable for testing drug activity, immunogenicity, and Fc-functional assays including CDC, ADCC, and ADCP activity. Svar's development capabilities cover nearly any pharmaceutical target, ensuring rapid and accurate assays.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The iLite® cell-based solutions are based on the iLite technology, a cleverly engineered cell-based assay system with a dual reporter gene readout. They offer the ease of use and robustness of a Ligand Binding Assay and can be developed for virtually any pharmaceutical target. They allow an easy, rapid, and accurate test format for measuring and quantifying drug activity and immunogenicity.
The iLite® cell-based solutions are supplied as cryopreserved assay ready cells, that are harvested and frozen at the same time, which means a higher reproducibility and overall superior performance compared to cells in culture can be obtained. Not the mention the time and cost you can reduce but not having to culture your cells!
Addressing the analytical gaps in modern therapeutic development
As biopharmaceuticals evolve toward complex modalities like gene therapies and immune-modulating biologics, traditional analytical methods often fall short. Cell-based assays are rising as essential tools but developing robust, context-specific solutions remains challenging.
Discover how tailored cell-based assay strategies can overcome these hurdles and support regulatory-ready data generation. Explore the key challenges and find practical guidance to help advance your analytical capabilities for next-generation therapeutic development.
Partnering for success in a new era of advanced therapeutics
From biologics to gene therapies, learn how Svar Life Science is helping drug developers discover and validate the next wave of modern medicines
